InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
17,013.60
(
0.91%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.20
(
0.78%
)
Bitcoin
57,889.06
(
-0.60%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: OverDraught post# 243142

Sunday, 07/10/2022 7:36:20 PM

Sunday, July 10, 2022 7:36:20 PM

Post# of 251670
That’s a standout adage! What ICPT is doing looks like a variant on Zebra’s Law. I.e., ICPT has an approved drug (Ocaliva for PBC), but the approved indication is too narrow for the company to become profitable. Hence, ICPT continues to seek Ocaliva approval for NASH despite the drug’s utter unsuitability for that indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up